Newly appointed CEO, Dr Alexandra Andrews said, “The Company has accelerated its commercial discussions with several strategic pharmaceutical companies who have been following the trial’s progress. What cannot be underestimated is the application of our full spectrum strain to other neurological disorders which will now be accelerated considering the current ASD results.”
NTI Price at posting:
5.7¢ Sentiment: Buy Disclosure: Held
